From Our Partners
Sunday, June 26, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

Call for Proposals on Ebola and Other Filoviruses

by Global Biodefense Staff
November 17, 2014
Ebola Drug Research at UTMB

The European Innovative Medicines Initiative (IMI) has launched a new joint Call for Proposals for the “Ebola and Other Filoviral Haemorrhagic Fevers Programme,” otherwise known as the Ebola+ Programme.

The topics proposed cover actions that will address short term challenges of the current epidemic as well as actions needed to address Ebola virus disease and other filoviral haemorrhagic fevers in a sustainable way for the long-term.

To address the present challenges of the ongoing epidemic, the following topics are launched under fast track single-stage procedures:

  • Topic 1: Vaccine development Phase I, II, and III
  • Topic 2: Manufacturing capability
  • Topic 3: Stability of vaccines during transport and storage
  • Topic 4: Deployment and compliance of vaccination regimens
  • Topic 5: Rapid diagnostic tests

IMI indicated additional topics under the Ebola+ Programme may be launched at a later point covering the following areas:

  • Immunotherapy
  • Formulations for cold chain
  • Rapid diagnostic tests – long term
  • Antivirals development and repurposing
  • Multivalent filovirus vaccine development

The IMI is a public-private partnership, between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA) in the life sciences area and launched in the year 2008.

Estimated funding for the effort is €140 million. Further details are available under the IMI Solicitation (.pdf). Proposals are due by December 1, 2014.

From Our Partners
Tags: AntiviralsEbolaEmerging ThreatsMarburgRequest for ProposalsVaccines

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America
Infectious Diseases

Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America

June 10, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC